Welcome to our dedicated page for ARTIVION SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artivion, Inc. filings document the regulatory record for a medical device company focused on aortic disease and related tissue preservation services. Recent Form 8-K disclosures furnish quarterly and annual operating results, clinical and regulatory updates, material agreements, and capital-structure matters, including credit-facility amendments and secured delayed draw term loan financing.
Proxy materials describe annual meeting voting, board governance, executive compensation, and shareholder matters. Other current reports document leadership appointments, material contracts, facilities-related agreements tied to the company’s operations, and disclosures connected to products such as aortic stent grafts, On-X mechanical heart valves, surgical sealants, and implantable cardiac and vascular human tissues.
ARTIVION, INC. (AORT) reports that officer Andrew M. Green, SVP, Regulatory and Quality, sold 11,480 shares of common stock on September 10, 2026 in a sale classified as an open market or private transaction at a weighted average price of $24.97 per share. After this sale, he directly holds 40,160 shares of ARTIVION common stock. No Rule 10b5-1 trading plan is reported for this transaction, and the price reflects a weighted range between $24.84 and $25.235 per share.
ARTIVION, INC. (AORT) is named as the issuer in a Rule 144 notice filed for sales of its common stock for the account of officer Andrew M. Green, using Fidelity Brokerage Services LLC. The notice lists 11,480 common shares with related figures of $286,656.62 and 48,756,221 as of September 10, 2026, and discloses several prior 2026 common stock sales. It also notes upcoming sales tied to restricted stock vesting events in February 2026 reported as compensation.
ARTIVION, INC. (AORT) reported that Andrew M. Green, its SVP, Regulatory and Quality, sold a total of 8,003 shares of common stock in two open-market transactions. On September 2, 2026 he sold 6,510 shares at a weighted average price of $27.265, and on September 3, 2026 he sold 1,493 shares at a weighted average price of $26.016. The price figures are footnoted as weighted averages over ranges of individual sale prices, and no Rule 10b5-1 trading plan is reported.
ARTIVION, INC. (AORT) officer Andrew M. Green filed a notice under Rule 144 stating an intention to sell common stock through Fidelity Brokerage Services LLC. The notice covers 1,493 shares of common stock with an aggregate market value of $38,842.13 as of September 3, 2026, to be sold on the NYSE.
The shares relate to restricted stock awards vesting on November 11, 2025 (459 shares) and February 22, 2026 (1,034 shares), both received from the issuer as compensation. The filing also reports prior sales over the past three months totaling 44,001, 616, and 6,510 shares for proceeds of $910,753.51, $17,586.18, and $177,497.82, respectively.
ARTIVION, INC. (AORT) officer Andrew M. Green filed a Rule 144 notice covering the potential sale of up to 6,510 shares of common stock. These shares have an aggregate market value of $177,497.82, with 48,756,221 common shares outstanding as of September 2, 2026.
The notice references shares tied to restricted stock vesting events scheduled for November 7, 10, and 11, 2025. It also reports prior sales in the last three months and is signed by Fidelity Brokerage Services LLC as attorney-in-fact for Andrew M. Green.
ARTIVION, INC. (AORT) is the issuer of common stock covered by a notice of proposed sale on Form 144 filed for the account of Marshall S. Stanton. The filing lists a total of 7,400 shares of common stock held at Fidelity Brokerage Services LLC with a stated market value of $198,694.54 as of August 27, 2026.
The securities to be sold consist of shares acquired through an ESPP purchase of 316 shares on December 31, 2025 and restricted stock vesting of 6,648 shares on February 22, 2026 and 436 shares on February 23, 2026. The transaction is being executed under Rule 144, with Fidelity acting as attorney-in-fact and broker for the seller.
ARTIVION, INC. (AORT) reported that President & CEO James P. Mackin sold 70,000 shares of common stock on 2026-08-19 in an open market or private transaction. The shares were sold at a weighted average price of $28.955 per share, with individual sale prices ranging from $28.89 to $29.15. Following this transaction, Mackin directly holds 877,275 shares of ARTIVION common stock. The transaction was not marked as made under a Rule 10b5-1 trading plan.
ARTIVION, INC. (AORT) has a notice of proposed sale of restricted or control securities under Rule 144 filed on behalf of officer James P. Mackin. The filing covers up to 70,000 shares of common stock, with an indicated aggregate market value of $2,053,100.00, to be sold through Fidelity Investments on the NYSE.
The shares were originally issued by the company as compensation for services rendered on several dates, including November 7, 2025 (21,405 shares), November 10, 2025 (21,880 shares), November 11, 2025 (21,879 shares), and February 22, 2026 (4,836 shares). National Financial Services LLC, via attorney-in-fact Jason Coleman, signed the notice for Mackin.
ARTIVION, INC. executive Andrew M. Green, SVP, Regulatory and Quality, reported a sale of 616 shares of common stock on 2026-08-14 at $28.549 per share. According to the company’s disclosure, these shares were sold in a “sell to cover” transaction solely to satisfy tax withholding obligations upon vesting of restricted stock units and did not represent a discretionary trade. Following this transaction, Green directly holds 59,643 shares of ARTIVION common stock.
Artivion, Inc. (AORT) reported that executive officer Lance A. Berry, EVP, COO, CFO & Treasurer, had 715 shares of common stock sold on his behalf on 2026-08-14 at $28.549 per share. According to the company, this was a non-discretionary “sell to cover” transaction to satisfy tax withholding obligations upon vesting of restricted stock units, and Berry’s directly held stake after the sale was 210,112 shares.